APVO News and Press, Aptevo Therapeutics Inc. From 03/05/24

Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA / A...

SEATTLE, WA / ACCESSWIRE / March 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) (" Aptevo " or the " Company "), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-44 (the " Reverse Stock Split "). The Reverse Stock Split is...

2023-11-22 16:19:18 ET More on Aptevo Therapeutics Seeking Alpha’s Quant Rating on Aptevo Therapeutics Historical earnings data for Aptevo Therapeutics Financial information for Aptevo Therapeutics For further details see: Aptevo Therapeutics files...

2023-11-14 09:46:59 ET More on Aptevo Therapeutics Seeking Alpha’s Quant Rating on Aptevo Therapeutics Historical earnings data for Aptevo Therapeutics Financial information for Aptevo Therapeutics For further details see: Aptevo Therapeutics GAAP ...

The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML Ongoing Extended Cash Runway with $7 Million in Funding and Potential for Additional $9....

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Aptevo Therapeutics Inc. (APVO) is expected to report $-0.72 for Q3 2023

SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the ...

2023-08-10 10:53:11 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): Q2 GAAP EPS of -$1.23 misses by $0.11 . Aptevo had cash and cash equivalents as of June 30, 2023 totaling $21.0 million (exclusive of the proceeds from the equity raised closed on August 4, 2023...

Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML APVO436 Poised for Phase 2 Trial Initiation Later in 2H23 Company Completes $5 million Equity Raise, Extending Cash Runway into 3Q24 SEATTLE, WA / ACCESSWIRE / A...